# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emily Dickinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI023-SYN
- Date: 2026-02-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucinda Hartwell, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-week kidney and blood pressure review; nephrology consultation and kidney ultrasound on the same trip. **S**

## History of present illness

Ms. Dickinson comes to the clinic for the first time in two years, on a quiet early appointment that combines this review, a kidney ultrasound, and her nephrology consultation so that she makes one trip. She started losartan 50 mg, atorvastatin 20 mg, and vitamin D3 three weeks ago and stopped naproxen. Her headaches are less frequent, about twice a week, and she takes acetaminophen for them. The morning nausea has eased. She has had no lightheadedness, cough, or muscle aches. Her home blood pressure averages 150/90 on her own upper-arm cuff, which read within 4 mmHg of the clinic device today. She has cut down on salted foods. She saw Dr. Adeyemi of nephrology this morning after the ultrasound. **S**

| Element | Detail |
|---|---|
| Headaches | About twice a week, down from most days; acetaminophen helps; no naproxen |
| Medication tolerance | No lightheadedness, cough, or muscle aches |
| Home blood pressure | Average 150/90 mmHg; her cuff agrees with the clinic device |
| Diet | Less salted and processed food |
| Access | One combined clinic trip for review, ultrasound, and nephrology |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Headaches about twice a week, milder; no visual change or weakness |
| Gastrointestinal | Negative | Morning nausea eased; no vomiting |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Genitourinary | Negative | No blood in the urine, frothy urine, or urinary symptoms |

5 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/88 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 53.8 kg; BMI 20.2 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 24 mmol/L; BUN: 22 mg/dL (high); Creatinine: 1.26 mg/dL (high); eGFR: 51 mL/min/1.73 m² (low); Glucose: 90 mg/dL; Urine albumin-creatinine ratio: 262 mg/g (high). All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Bicarbonate (total CO2): 24 mmol/L at baseline, 24 mmol/L at this visit **S**
- BUN: 21 mg/dL at baseline, 22 mg/dL (high) at this visit **S**
- Creatinine: 1.2 mg/dL (high) at baseline, 1.26 mg/dL (high) at this visit **S**
- eGFR: 54 mL/min/1.73 m² (low) at baseline, 51 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 90 mg/dL at this visit **S**
- Urine albumin-creatinine ratio: 240 mg/g (high) at baseline, 262 mg/g (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Slight, composed, and a little tired after the trip; asked to wait in a quiet side room rather than the waiting area |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Abdomen | Soft; no renal bruit |
| Mental status | Alert and precise; mood "better"; reactive affect |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3a A2** (N18.31). Three weeks after starting losartan, potassium 4.6 mmol/L and creatinine 1.26 mg/dL (eGFR 51, a 5 percent rise in creatinine), well within the accepted rise. A second urine albumin-creatinine ratio of 262 mg/g confirms persistent A2 albuminuria. Ultrasound shows normal-sized kidneys with mildly increased echogenicity and no obstruction. Nephrology agrees that hypertensive kidney disease is the probable cause and that no biopsy is needed. **S**
   - Increase losartan to 100 mg daily.
   - Start dapagliflozin 10 mg daily, as nephrology advised.
   - Potassium and creatinine in four weeks, drawn at home by the mobile phlebotomy service, with a video visit the same day.
   - Sick-day rules explained: pause losartan and dapagliflozin during vomiting, diarrhea, or poor intake, and call.
2. **Hypertension with chronic kidney disease** (I12.9). 148/88 mmHg in the clinic and 150/90 at home, improving but above the KDIGO systolic target of below 120. **S**
   - Losartan increase as above; continue home readings and send them weekly.
3. **Vitamin D deficiency** (E55.9). Taking vitamin D3 daily. **S**
   - Recheck 25-hydroxyvitamin D, calcium, phosphate, and PTH at six to twelve months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine after starting an ARB | 2 to 4 weeks after starting or increasing an ACE inhibitor, ARB, SGLT2 inhibitor, or MRA | Completed today | Potassium 4.6 mmol/L, creatinine 1.26 mg/dL, eGFR 51, three weeks after starting losartan |
| Laboratory | Urine albumin-creatinine ratio, confirmatory | Repeat to confirm albuminuria at diagnosis; then with each eGFR draw | Completed today | 262 mg/g, confirming A2 (240 mg/g at intake) |
| Imaging | Kidney ultrasound | At diagnosis when the cause is uncertain; no routine surveillance imaging | Completed today | Normal-sized kidneys, mildly echogenic; no obstruction, stones, or cysts |
| Referral | Nephrology consultation | At diagnosis of albuminuric chronic kidney disease in a younger adult; or when KFRE or eGFR thresholds are met | Completed today | Seen today; agrees with hypertensive kidney disease and advises dapagliflozin and a maximum-dose ARB |
| Examination | Standardized office and home blood pressure | Every visit | Completed today | 148/88 mmHg in the clinic after five minutes' rest, average of two readings; home average 150/90 |
| Examination | Weight and cardiac auscultation | Every visit | Completed today | 53.8 kg; regular rhythm, no murmur |
| Medication safety | Medication review: NSAID avoidance and dose adjustment | Every visit | Completed today | No naproxen since intake; acetaminophen twice a week; doses suit eGFR 51 |
| Medication safety | Statin tolerance | At each review after starting | Completed today | No muscle aches on atorvastatin 20 mg |
| Laboratory | Calcium, phosphate, PTH, and 25-hydroxyvitamin D | Baseline at G3a, then every 6 to 12 months | Up to date | Baseline at intake: PTH 74 pg/mL and vitamin D 21 ng/mL; on vitamin D3; recheck at six to twelve months |
| Laboratory | Hemoglobin | At least yearly in G3 | Up to date | 12.3 g/dL at intake |
| Survey | KFRE 2- and 5-year risk | Yearly in G3 to G5 | Up to date | 0.5 and 1.6 percent at intake, below referral thresholds |
| Survey | PHQ-9 | Yearly with hypertension; repeat if symptoms change | Up to date | 6 at intake, mostly from tiredness and poor sleep with headaches |
| Self-management | Sodium, home blood pressure, and sick-day rules | Every visit | Completed today | Less salted food; weekly home readings; sick-day rules explained verbally |

## Goal progress

- Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness. In progress; target 2026-09-28. **S**
- Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor. In progress; target 2026-06-01. **S**
- Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip. In progress; target 2026-09-28. **S**
- 25-hydroxyvitamin D of at least 30 ng/mL. In progress; target 2026-09-28. **S**
- Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic. In progress; target 2026-09-28. **S**

## Medication changes

- Stopped: Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Started: Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Started: Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney Int 2021;99(3S):S1-S87)
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017), American College of Cardiology and American Heart Association (Hypertension 2018;71(6):e13-e115)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026), Aether Forge

## Follow-up

- Video visit in four weeks with home vital signs and home blood tests for potassium and creatinine. **S**
- Next scheduled visit 2026-03-02: video visit four weeks after the losartan increase and dapagliflozin start, with home vital signs and home blood tests. **S**
